# NCT02426086 (NCT02426086)

> Study to Evaluate Activity of 2 Dose Levels of Imetelstat in Participants With Intermediate-2 or High-Risk Myelofibrosis (MF) Previously Treated With Janus Kinase (JAK) Inhibitor

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02426086
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Geron Corporation
- Conditions: Myelofibrosis
- Interventions: Imetelstat 4.7 mg/kg; Imetelstat 9.4 mg/kg
- Enrollment: 107
- Primary outcome: Percentage of Participants With Spleen Response
- Primary outcome: Percentage of Participants With Symptom Response

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 2
- Bluesky threads: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct02426086